Catheter Precision, Inc. — Form 8-K Summary
Reporting context: Report dated October 2, 2026, covering the September 30, 2026 annual meeting and related corporate actions. The filing reports governance, equity and capital-structure changes; it does not provide quarterly or annual operating results. The company announced a change of name to Flyte Aviation, Inc.
Financial and operating metrics
The filing provides no revenue, profit, cash-flow, margin, debt or liquidity figures, and no comparable-period financial data. It does not provide financial guidance.
Material developments
- Reverse stock split and name change: A 1-for-10 reverse split and the name change to Flyte Aviation, Inc. are scheduled to take effect at 12:01 a.m. ET on October 5, 2026. The stock is expected to begin trading that day on NYSE American under ticker VJET, with a new CUSIP. Shares outstanding are expected to fall from approximately 21,019,874 to 2,101,987; authorized capital remains 500 million common and 10 million preferred shares.
- The split will proportionately adjust outstanding options, warrants, preferred-stock conversion terms and equity-plan share amounts. Fractional shares will be aggregated and sold, with holders receiving their pro rata share of net proceeds after customary costs. The company says the split will not otherwise change holders’ proportional ownership or voting power.
- Equity plan: Stockholders approved adding 5,000,000 pre-split shares to the 2023 Equity Incentive Plan reserve.
- Option repricing: Outstanding options with exercise prices above fair market value were repriced to $0.152 per share, based on the September 30 closing price. The split is expected to adjust that price to $1.52. Option share counts, expiration dates and vesting schedules are unchanged by the repricing. The filing identifies options held by CEO David A. Jenkins (89,999 shares) and CFO Philip Anderson (66,315 shares), as of August 18, 2026.
- Stockholders approved reincorporation from Delaware to Nevada, an amendment allowing the board to reduce the Series J preferred-stock conversion price subject to stated limits, and issuance of up to 340,000 pre-split shares upon exercise of Series M warrants. The filing does not state that these shares have been issued.
- All eight annual-meeting proposals passed. Approximately 12.34 million of 18.97 million shares eligible to vote were represented, or about 65.1%. David A. Jenkins was elected as a Class II director for a term expiring at the 2029 annual meeting, subject to the filing’s stated qualification related to reincorporation.
Outlook, risks and unusual items
No business outlook or operating guidance is provided. The equity-plan increase and potential warrant exercises may create dilution; the reverse split itself does not change authorized share counts. The filing does not quantify the potential dilution, financial effect of the repricing, or costs associated with the corporate changes. The name change does not require stockholders to take action; holders of record may contact Equiniti with questions about the split or fractional-share proceeds.
Important facts for investors to verify
- Confirm the October 5 effective date, split-adjusted share count, ticker VJET and new CUSIP.
- Review the amended equity plan and determine how the additional share reserve and potential warrant exercises affect dilution.
- Check the terms and status of the Series J conversion-price amendment and Series M warrants.
- Verify completion and timing of the Nevada reincorporation, including any related governance changes.
- Consult subsequent filings for financial results, cash needs, operating outlook and any updates to these actions.